bDMARDs approved for RA include four different modes of action: tumor necrosis factor α (TNF-α) inhibition, inhibitors of co-stimulation, interleukin-6 (IL-6) receptor inhibition, and the depletion of B cells (12, 14–16). The gene discussed is TNF; the disease is rheumatoid arthritis.